Biogen Inc. (BIIB) vs Medline Inc. (MDLN)
A side-by-side comparison of Biogen Inc. and Medline Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.
BIIB
Biogen Inc.
$205.61HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
MDLN
Medline Inc.
$40.51HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
Total return — BIIB vs MDLN
growth of $100 · dividends reinvested · last 1yBIIB +16.1%MDLN -3.2%BIIB compounded faster
BIIB MDLN
BIIB vs MDLN: by the numbers
- •MDLN is the larger company ($34.26B vs $30.36B market cap).
- •BIIB trades at the lower trailing earnings multiple (21.43 vs 32.81 P/E), one valuation lens rather than an overall verdict.
- •BIIB converts more revenue to profit (13.92% vs 3.31% net margin).
Metrics side by side
Valuation
| Metric | BIIB | MDLN |
|---|---|---|
| P/E ratio | 21.43 | 32.81 |
| Forward P/E | 15.71 | 26.21 |
| P/S ratio | 3.01 | 1.12 |
| P/B ratio | 1.59 | 2.91 |
| EV / EBITDA | 13.53 | 14.47 |
| FCF yield | 8.83% | 4.66% |
Profitability
| Metric | BIIB | MDLN |
|---|---|---|
| Gross margin | 69.77% | 24.04% |
| Operating margin | 15.65% | 7.04% |
| Net margin | 13.92% | 3.31% |
| ROE | 7.36% | 8.55% |
| ROIC | 6.62% | 5.69% |
Growth (annualized)
| Metric | BIIB | MDLN |
|---|---|---|
| Revenue CAGR (5Y) | -4.80% | N/A |
| EPS CAGR (5Y) | -18.67% | N/A |
| FCF CAGR (5Y) | -3.59% | N/A |
| Total return CAGR (5Y) | -9.48% | N/A |
Frequently asked
- Which has the lower trailing P/E, BIIB or MDLN?
- BIIB has the lower trailing P/E: BIIB trades at 21.43 and MDLN at 32.81. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Is BIIB or MDLN more profitable?
- BIIB runs the higher net margin — BIIB at 13.92% versus MDLN at 3.31%.
Go deeper
Dig into the metrics
Biogen P/E ratioMedline P/E ratioBiogen dividend yieldMedline dividend yieldBiogen ROEMedline ROEBiogen operating marginMedline operating marginBiogen revenue growthMedline revenue growthBiogen free cash flowMedline free cash flow
Biogen & Medline appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.